Compare Adobe Systems Inc (ADBE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs Summit Therapeutics Inc — how do they compare? Adobe Systems Inc trades at $221.08 (market cap $88.06B), while Summit Therapeutics Inc trades at $15.74 (market cap $12.32B). The key difference: Adobe Systems Inc is far larger — about 7.1× Summit Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ADBE | SMMT | |
|---|---|---|
Market Cap | $88.06B | $12.32B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $29.32 |
52-Week Low | $193.41 | $13.05 |
Enterprise Value | $89.50B | $11.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) trades at $220.92, up 1.31% with a bullish technical signal despite recent volatility. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $5.96 versus $5.82, revenue growth to $23.77B in 2025, and robust profitability margins. However, negative net cash flow of -$2.18B in 2025 and AI competition concerns from recent news create mixed sentiment.
Outlook remains positive with a consensus price target of $246.75, representing 11.7% upside, supported by 49.21% analyst buy ratings. Key risks include AI disruption fears and CEO transition uncertainty, but Adobe's entrenched market position and double-digit growth provide a solid foundation for long-term investors.
Summit Therapeutics (SMMT) trades at $15.93, up 3.31% today, with a bullish technical signal despite mixed moving averages and overbought RSI readings. The company reported a net loss of -$1.08B in 2025 and negative ROE/ROA, but recent Phase III trial success for ivonescimab in lung cancer has driven optimism. Cash flow remains volatile, with 2025 net cash flow positive at $120.4M but turning negative in 2026 projections.
Outlook hinges on ivonescimab's regulatory approval and commercial potential, with a consensus price target of $22.93 implying 44% upside. High volatility and binary clinical outcomes pose significant risks, but strong analyst buy ratings (66.7%) reflect confidence in the drug's prospects. Investors face substantial dilution risk from a proposed $500M stock offering announced June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
